Ogastoro (Lansoprazole)

Lansoprazole, the active ingredient in Ogastoro, is a proton pump inhibitor presented as a 30 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Ogastoro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: accelerates ulcer healing and reduces risk of recurrence. - Helicobacter pylori eradication regimens: used as part of combination therapy to increase eradication rates. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - NSA‑induced gastropathy prophylaxis: lowers risk of ulcer formation in high‑risk patients.

Adverse reactions to lansoprazole are generally mild to moderate, but serious events can occur.

Common Side Effects: - Headache: mild, transient headache reported in clinical trials. - Diarrhoea: loose stools, usually self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation with reduced urine output. - Severe hypersensitivity reactions: rash, angio‑edema, or anaphylaxis. - Osteoporotic fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Thrombotic thrombocytopenic purpura: rare blood clotting disorder. - Vitamin B12 deficiency: reduced absorption leading to anaemia over prolonged therapy.

When prescribing lansoprazole, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for altered drug levels. - Monitor long‑term users: watch for bone density loss and vitamin B12 deficiency. - Pregnancy and lactation: weigh benefits against potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise systemic exposure. - Digoxin: modest rise in serum concentrations. - Ketoconazole and other azole antifungals: lower absorption, consider alternative agents.